Cordis Launches SELUTION SLR Drug-Eluting Balloon in Japan for Peripheral Artery Disease Treatment

Key Takeaways

• Cordis officially launches SELUTION SLR PTA Drug-Eluting Balloon in Japan for peripheral artery disease treatment
• Clinical trial results demonstrate durable outcomes in complex patient populations with peripheral arterial conditions
• Japanese patients now have access to advanced drug-eluting balloon technology for minimally invasive vascular interventions

---

TOKYO - Cordis, a leading interventional cardiovascular technology company, has announced the commercial launch of its SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan, expanding treatment options for patients with peripheral artery disease.

Advanced Balloon Technology Now Available

The SELUTION SLR represents a significant advancement in drug-eluting balloon technology, designed specifically for percutaneous transluminal angioplasty (PTA) procedures. This medical device combines balloon catheter technology with targeted drug delivery to treat narrowed or blocked peripheral arteries.

Clinical Evidence Supporting Launch

The Japan launch follows successful clinical trials demonstrating the device’s effectiveness in treating complex patient populations. The SELUTION SFA Japan clinical trial showed durable clinical outcomes, providing evidence for the balloon’s long-term efficacy in peripheral arterial interventions.

Market Impact and Patient Access

This launch positions Cordis to compete in Japan’s growing peripheral intervention market, where aging demographics drive increased demand for minimally invasive vascular treatments. Japanese interventional cardiologists and vascular specialists now have access to this drug-eluting balloon technology for treating patients with peripheral artery disease.

The availability of SELUTION SLR in Japan represents Cordis’s continued global expansion strategy, bringing proven cardiovascular technologies to international markets. The device offers an alternative to traditional balloon angioplasty and surgical interventions for appropriate patient populations.

Regulatory Approval and Distribution

The commercial launch indicates successful completion of Japan’s regulatory approval process, allowing Cordis to market and distribute the SELUTION SLR through established healthcare channels. This regulatory milestone enables Japanese hospitals and catheterization laboratories to incorporate the technology into their peripheral intervention programs.

---

Frequently Asked Questions

What conditions does the SELUTION SLR Drug-Eluting Balloon treat?

The SELUTION SLR is designed to treat peripheral artery disease by opening narrowed or blocked arteries in the legs and other peripheral vessels during minimally invasive procedures.

When will Japanese patients have access to this treatment?

The device is now commercially available in Japan following Cordis’s official launch announcement, meaning qualified patients can access this treatment through participating hospitals and medical centers.

How does this drug-eluting balloon differ from standard balloon angioplasty?

Unlike standard balloons, the SELUTION SLR delivers medication directly to the artery wall during inflation, potentially reducing the risk of re-narrowing and improving long-term outcomes compared to plain balloon angioplasty.